Is There a Role for Proton Therapy in the Treatment of Breast Cancer?
Locoregional management strategies have considerably evolved.  Considerable progress has been made in understanding which patients will benefit from radiation therapy and ways to administer treatment that maximize clinical benefit while minimizing toxicity; however, many controversies exist as we
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Principles of Breast Reconstruction after Surgery
All women undergoing breast cancer treatment should be educated about breast reconstructive options as adapted to their individual clinical situation and be offered an opportunity to consult with a reconstructive plastic surgeon. Coordinating consultation and surgical treatment with a reconstruct
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Management of Rare Breast Cancers
The management of rare breast cancer subtypes represents a challenge in clinical practice.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Biomarker Assays for Treatment Selection of Advanced Breast Cancer
Biomarkers identify patients who are likely to respond to a given therapy. These assays and their interpretation can present challenges for clinicians.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Management of Metastatic Breast Cancer, Including SABCS Updates
The decision-making process for metastatic breast cancer should involve a detailed discussion with patients of the benefits and risks associated with all possible treatment strategies.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Management of Toxicities with Targeted Therapies for Breast Cancer
Staying up-to-date with the available treatment options is important to clinicians integrating new evidence-based data into their clinical practice, and being familiar with their toxicity profiles is important to optimize patient outcomes.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Practical Application of Immuno-Oncology in Renal Cell Carcinoma
The goal of this activity is to improve participants’ competence in and performance at applying practice-changing clinical data, expert recommendations, and guidelines to optimize the use of immuno-oncology–based combinations in the care of their patients with RCC.
Category
  • Kidney Cancer
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Multiple Myeloma
Discussing specific patient cases, providing the rationale for the treatment choices based on expert experience and recent data from trials, and outlining strategies to provide adequate supportive care will assist clinicians treating transplant ineligible and elderly patients with multiple myeloma in making optimal treatment decisions and improving patient outcomes.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lung Cancer
For each of the emerging therapies described (bevacizumab, PARP inhibitors, and HIPEC), the treatment settings, patient selection criteria, and other therapies used in conjunction have varied widely across clinical trials. This has led to much discussion and likely confusion regarding the exact clinical contexts in which these new options should be considered.
Category
  • Lung Cancers
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • CCM clock hours
  • Participation
Practical Use of Next Generation Sequencing in Metastatic Disease
Next generation sequencing methods are increasingly being utilized to match patients with targeted therapies.
Category
  • Diagnostics
Format
  • Enduring Activity
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation

Pages